Patents Examined by Marianne P. Allen
  • Methods for treating metabolic disorders using FGF
    Patent number: 9808508
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 7, 2017
    Assignee: Salk Institude for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 9801923
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: October 31, 2017
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Therapeutic use of antibodies to HGF
    Patent number: 9783603
    Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 10, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Andrew Lawrence Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
  • Angiopoietin-like 4 antibodies and methods of use
    Patent number: 9771417
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 26, 2017
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • Treatment of obesity
    Patent number: 9765129
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: September 19, 2017
    Assignees: Baker Medical Research Institute, Christian-Albrechts-Universität zu Kiel
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity
    Patent number: 9758579
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: September 12, 2017
    Assignee: ALDER BIOHOLDINGS, LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, Ethan Ojala, Brian Kovacevich, John Latham, Jeffrey T. L. Smith
  • Apelin fusion proteins and uses thereof
    Patent number: 9751921
    Abstract: The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: September 5, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Panayiotis Stevis, Andrew Murphy
  • Therapeutic use of antibodies to HGF
    Patent number: 9732150
    Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 15, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
  • Treatment of inflammatory skin disease
    Patent number: 9724409
    Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: August 8, 2017
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Vesicles comprising epidermal growth factor and compositions thereof
    Patent number: 9717776
    Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: August 1, 2017
    Assignees: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA, CONSEJO SUPERIOR DE INVESTIGACIONES CENTÍFICAS
    Inventors: Héctor Jesús Santana Milián, Leonor Ventosa Rull, Eduardo Martínez Díaz, Jorge Amador Berlanga Acosta, Ingrid Cabrera Puig, Jaume Veciana Miró
  • Anti c-Met antibodies
    Patent number: 9688774
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: June 27, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge
  • Anti-ACTH antibodies and use thereof
    Patent number: 9688754
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 27, 2017
    Assignee: ALDER BIOPHARMACEUTICALS, INC.
    Inventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
  • Biological materials related to c-Met
    Patent number: 9683045
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: June 20, 2017
    Assignee: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • Fibulin protein variants and corresponding nucleic acid sequences
    Patent number: 9676834
    Abstract: Embodiments of the invention provide to fibulin 3 (also referred to as EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1)) polypeptide variants, and nucleotide sequences that code for them, characterized by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: June 13, 2017
    Inventor: Yihong Zhou
  • Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
    Patent number: 9676846
    Abstract: Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 13, 2017
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Qi Zhao
  • Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
    Patent number: 9675671
    Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: June 13, 2017
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
    Patent number: 9670275
    Abstract: The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: June 6, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Hilde Adi Pierrette Revets, Jo Vercammen, Augustinus Antonius Maria Silvester van Dongen
  • Cytokines and neuroantigens for treatment of immune disorders
    Patent number: 9669090
    Abstract: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: June 6, 2017
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Treatment and prevention of radiation injury using MFG-E8
    Patent number: 9669070
    Abstract: Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8).
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: June 6, 2017
    Assignee: The Feinstein Institute For Medical Research
    Inventor: Ping Wang
  • Chimeric fibroblast growth factor 23 proteins and methods of use
    Patent number: 9657075
    Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 23, 2017
    Assignee: New York University
    Inventors: Moosa Mohammadi, Regina Goetz